文献速递糖尿病肥胖与代谢综合征

度拉糖肽3.0 mg与4.5 mg对比1.5 mg在二甲双胍治疗2型糖尿病患者中的疗效与安全性:AWARD-11随机对照试验

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).
PubMed 文献 · Diabetes Care · 2021-01-04

AWARD-11研究将1842例二甲双胍控制不佳的2型糖尿病患者随机分配至每周一次度拉糖肽1.5 mg、3.0 mg或4.5 mg治疗52周。主要终点为36周时HbA1c降幅优效性;4.5 mg在两种估计目标下均优于1.5 mg,3.0 mg仅在疗效估计目标下优效;4.5 mg体重降幅亦优效,安全性与1.5 mg相似。

要点

  • 度拉糖肽4.5 mg较1.5 mg显著降低HbA1c(ETD -0.24%至-0.34%)和体重(ETD -1.6 kg)。
  • 度拉糖肽3.0 mg在疗效估计目标下HbA1c降幅优于1.5 mg(ETD -0.17%),但治疗方案估计目标下未达优效。
  • 常见不良事件为恶心和呕吐,发生率随剂量增加,但总体安全性特征相似。

核心结论

  • 在二甲双胍控制不佳的2型糖尿病患者中,度拉糖肽从1.5 mg增至3.0 mg或4.5 mg可提供临床相关的剂量依赖性HbA1c和体重降低,且安全性特征相似。

研究设计与样本

  • 随机对照试验,将1842例二甲双胍控制不佳的2型糖尿病患者随机分配至每周一次度拉糖肽1.5 mg、3.0 mg或4.5 mg,治疗52周。
  • 主要目标为36周时3.0 mg和/或4.5 mg对比1.5 mg在HbA1c降幅上的优效性,采用治疗方案和疗效两种估计目标分析。

主要发现

  • 36周时,4.5 mg对比1.5 mg的HbA1c降幅在治疗方案估计目标下为-1.77% vs -1.54%(ETD -0.24%,P<0.001),疗效估计目标下为-1.87% vs -1.53%(ETD -0.34%,P<0.001)。
  • 3.0 mg对比1.5 mg的HbA1c降幅在疗效估计目标下优效(ETD -0.17%,P=0.003),但在治疗方案估计目标下未达优效(ETD -0.10%,P=0.096)。
  • 36周时,4.5 mg对比1.5 mg的体重降幅在治疗方案估计目标下为-4.6 vs -3.0 kg(ETD -1.6 kg,P<0.001),疗效估计目标下为-4.7 vs -3.1 kg(ETD -1.6 kg,P<0.001)。
  • 至36周常见不良事件包括恶心(1.5 mg 13.4%;3 mg 15.6%;4.5 mg 16.4%)和呕吐(1.5 mg 5.6%;3 mg 8.3%;4.5 mg 9.3%)。

临床怎么用

  • 对于二甲双胍控制不佳的2型糖尿病患者,可考虑将度拉糖肽从1.5 mg上调至3.0 mg或4.5 mg以进一步改善血糖和体重。
  • 剂量上调时需关注恶心、呕吐等胃肠道不良事件的发生率增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare efficacy and safety of dulaglutide at doses of 3.0 and 4.5 mg versus 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin. RESEARCH DESIGN AND METHODS: Patients were randomly assigned to once-weekly dulaglutide 1.5 mg, 3.0 mg, or 4.5 mg for 52 weeks. The primary objective was determining superiority of dulaglutide 3.0 mg and/or 4.5 mg over 1.5 mg in HbA1c reduction at 36 weeks. Secondary superiority objectives included change in body weight. Two estimands addressed efficacy objectives: treatment regimen (regardless of treatment discontinuation or rescue medication) and efficacy (on treatment without rescue medication) in all randomly assigned patients. RESULTS: Mean baseline HbA1c and BMI in randomly assigned patients (N = 1,842) was 8.6% (70 mmol/mol) and 34.2 kg/m2, respectively. At 36 weeks, dulaglutide 4.5 mg provided superior HbA1c reductions compared with 1.5 mg (treatment-regimen estimand: -1.77 vs. -1.54% [-19.4 vs. -16.8 mmol/mol], estimated treatment difference [ETD] -0.24% (-2.6 mmol/mol), P < 0.001; efficacy estimand: -1.87 vs. -1.53% [-20.4 vs. -16.7 mmol/mol], ETD -0.34% (-3.7 mmol/mol), P < 0.001). Dulaglutide 3.0 mg was superior to 1.5 mg for reducing HbA1c, using the efficacy estimand (ETD -0.17% [-1.9 mmol/mol]; P = 0.003) but not the treatment-regimen estimand (ETD -0.10% [-1.1 mmol/mol]; P = 0.096). Dulaglutide 4.5 mg was superior to 1.5 mg for weight loss at 36 weeks for both estimands (treatment regimen: -4.6 vs. -3.0 kg, ETD -1.6 kg, P < 0.001; efficacy: -4.7 vs. -3.1 kg, ETD -1.6 kg, P < 0.001). Common adverse events through 36 weeks included nausea (1.5 mg, 13.4%; 3 mg, 15.6%; 4.5 mg, 16.4%) and vomiting (1.5 mg, 5.6%; 3 mg, 8.3%; 4.5 mg, 9.3%). CONCLUSIONS: In patients with type 2 diabetes inadequately controlled by metformin, escalation from dulaglutide 1.5 mg to 3.0 mg or 4.5 mg provided clinically relevant, dose-related reductions in HbA1c and body weight with a similar safety profile.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021. PMID: 33397768. doi:10.2337/dc20-1473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。